Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used to treat hepatocellular carcinoma. Tremelimumab is directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumors and reduces tumor growth.
Tremelimumab Biosimilar Antibody Production Strategy
Left panel: the plasmid diagram showing the lentiviral vector expressing Tremelimumab; right panel: the amino acid sequences of Tremelimumab heavy chain and light chain.
Tremelimumab Biosimilar Antibody
$205.00 – $2,500.00
Tremelimumab is a human immunoglobulin (Ig) G2-kappa monoclonal antibody against human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) protein.
Host/Isotype: Human/IgG2
Class: Monoclonal
Immunogen: Human CTLA-4 protein
Production platform: CHO cells
Purification: Affinity chromatography
Storage buffer: PBS, pH 7.2
Storage condition: –20°C
For Research Use Only. Not for use in clinical diagnostics or therapeutics.
Additional information
| Antibody Production Scale | 50 ug, 250 ug, 1 mg |
|---|---|
| Conjugate | None, FITC, HRP, ADC (custom drug) |
Be the first to review “Tremelimumab Biosimilar Antibody”
You must be logged in to post a review.
Related products
-
Best Seller
Methanol fixation and staining kit
Item Cat No.: BCASME
Application: IF on cryosection
Reactivity: Tissue
Read More -
Best Seller
Custom CAR-T Cell Development & Validation
Item Cat No.: BCTCAR
Application: CAR-T cell development
Reactivity: Cell culture
Read More -
Best Seller
Collagen fixation and staining kit
Item Cat No.: BCASCO
Application: IF on cryosection
Reactivity: Tissue
Read More
Reviews
There are no reviews yet.